Serum levels of adipokine retinol-binding protein-4 in relation to renal function.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 17630267.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Retinol-binding protein (RBP)-4 was recently identified as an adipokine that induces insulin resistance. In the current study, we investigated RBP-4 serum levels in diabetic and nondiabetic patients on chronic hemodialysis (CD) compared with control subjects with a glomerular filtration rate >50 ml/min. The majority of the diabetic subjects used oral hypoglycemic agents or insulin. RBP-4 was determined by enzyme-linked immunosorbent assay in control subjects (n = 59) and CD patients (n = 58) and correlated with clinical and biochemical measures of renal function, glucose and lipid metabolism, and inflammation in both groups. Mean serum RBP-4 levels were almost fourfold higher in CD patients (102 +/- 30 mg/l) compared with control subjects (28 +/- 8 mg/l). Furthermore, serum creatinine independently predicted RBP-4 concentrations in multiple regression analyses in both control subjects and CD patients. In addition, C-reactive protein and systolic blood pressure independently and negatively correlated with RBP-4 serum concentrations in CD patients but not control subjects. In contrast, markers of glucose and lipid metabolism were not independently related to serum RBP-4 in control subjects or CD patients. We show that markers of renal function are independently related to serum RBP-4 levels.
Medical subject headings
- Kidney Failure, Chronic
- Kidney Function Tests
- Renal Dialysis
- Retinol-Binding Proteins